Femasys Inc (FEMY)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$2.98-2.61%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · FEMY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -52.2% |
| Our one-year growth estimate | diamond | -14.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 38.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 26 industry peers · Company calendar date is not available
FEMY — private placement
Dated 2026-08-11
Entry into a Material Definitive Agreement. Private Placement On August 7, 2026, Femasys Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of (i) 5,013,559 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) pre-funded warran…
Why it matters: Updates on partnerships will indicate Femasys's ability to expand its market reach. This is key for growth.
Supportive ifLook for news about new partnerships or revenue from current ones.
Worry ifNo new partnerships or no updates from current ones.
Why it matters: Money from partnerships would prove Femasys's plan to reach more customers. This could help growth.
Watch forRevenue from partnerships exceeds $100,000 in Q3 2026.
Also watch forNo revenue from partnerships reported in Q3 2026.
Why it matters: Updates on cash will show if Femasys can fund operations and growth plans. It is crucial for ongoing stability.
Watch forCash and cash equivalents reported above $5 million in Q3 2026.
Also watch forCash and cash equivalents reported below $1 million in Q3 2026.
Why it matters: Enrollment progress is key for advancing FemBloc toward U.S. approval, impacting future revenue.
Supportive ifEnrollment in the FINALE trial is at least 50% of the target.
Worry ifEnrollment stalls or falls below 25% of target participants.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$377 on $10,000 · ±3.8% | How much price usually moves either way. |
| Bad day | $1,215 loss on $10,000 · 12.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,962 loss on $10,000 · 89.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Compliance status impacts investor trust and how the market views Femasys.
Worry ifFemasys is compliant with Nasdaq rules for two quarters in a row.
Less concerning ifFemasys gets a new notice of non-compliance from Nasdaq.
Why it matters: The new COO could bring fresh strategies to improve operations. This may affect overall performance.
Watch forThe new COO announced positive changes to operations in three months.
Also watch forNo big improvements in operations were reported in three months.
Why it matters: The company needs enough cash to fund operations after the stock split. A strong cash position is crucial for stability.
Supportive ifA press release shows cash reserves went up after the split. They are over $5 million.
Worry ifCash reserves fall below $3 million after the reverse stock split.
Why it matters: Sales growth shows FemaSeed is doing well. This is important for Femasys's plans.
Supportive ifSales of FemaSeed Complete increase by more than 10% compared to Q2 2026.
Worry ifSales of FemaSeed Complete decline or remain flat compared to Q2 2026.
Why it matters: Finishing enrollment is key for getting FemBloc approved by the FDA and selling it.
Supportive ifEnrollment in the FINALE trial is completed by the end of Q3 2026.
Worry ifEnrollment in the FINALE trial is delayed beyond Q3 2026.
Why it matters: A drop in cash could mean money problems. This can hurt operations and growth.
Worry ifCash and cash equivalents remain above $1 million at the end of Q3 2026.
Less concerning ifCash and cash equivalents fall below $1 million by the end of Q3 2026.
Why it matters: New partnerships could help Femasys's products reach more customers and make more money.
Supportive ifAnnouncement of at least one new strategic partnership by the end of Q3 2026.
Worry ifNo new partnerships announced by the end of Q3 2026.